Daquiran

RSS

pramipexole

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Daquiran has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 23/05/2006

Authorisation details

Product details
Name
Daquiran
Agency product number
EMEA/H/C/000135
Active substance
pramipexole dihydrochloride monohydrate
International non-proprietary name (INN) or common name
pramipexole
Therapeutic area (MeSH)
Parkinson Disease
Anatomical therapeutic chemical (ATC) code
N04BC05
Publication details
Marketing-authorisation holder
Dr. Karl Thomae GmbH
Revision
5
Date of issue of marketing authorisation valid throughout the European Union
27/10/1997
Contact address
Birkendorfferstr. 65
D-88397 Biberach/Riss
Germany

Product information

02/02/2006 Daquiran - EMEA/H/C/000135 -

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Anti-Parkinson drugs

Therapeutic indication

DAQUIRAN tablets are indicated for treatment of the signs and symptoms of advanced idiopathic Parkinson's disease in combination with levodopa, i.e. over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or "on off" fluctuations).

How useful was this page?

Add your rating